Amphastar Pharmaceuticals Inc
NASDAQ:AMPH
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
36.99
63.45
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one AMPH stock under the Base Case scenario is 62.15 USD. Compared to the current market price of 45.46 USD, Amphastar Pharmaceuticals Inc is Undervalued by 27%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Amphastar Pharmaceuticals Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for AMPH cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Amphastar Pharmaceuticals Inc
Balance Sheet Decomposition
Amphastar Pharmaceuticals Inc
Current Assets | 545.9m |
Cash & Short-Term Investments | 250.5m |
Receivables | 145m |
Other Current Assets | 150.5m |
Non-Current Assets | 999.2m |
PP&E | 327.5m |
Intangibles | 594.8m |
Other Non-Current Assets | 76.9m |
Current Liabilities | 159m |
Accounts Payable | 34.1m |
Accrued Liabilities | 123.4m |
Other Current Liabilities | 1.5m |
Non-Current Liabilities | 658.5m |
Long-Term Debt | 596.4m |
Other Non-Current Liabilities | 62m |
Earnings Waterfall
Amphastar Pharmaceuticals Inc
Revenue
|
723.5m
USD
|
Cost of Revenue
|
-340.2m
USD
|
Gross Profit
|
383.3m
USD
|
Operating Expenses
|
-169.1m
USD
|
Operating Income
|
214.3m
USD
|
Other Expenses
|
-56.5m
USD
|
Net Income
|
157.7m
USD
|
Free Cash Flow Analysis
Amphastar Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
AMPH Profitability Score
Profitability Due Diligence
Amphastar Pharmaceuticals Inc's profitability score is 68/100. The higher the profitability score, the more profitable the company is.
Score
Amphastar Pharmaceuticals Inc's profitability score is 68/100. The higher the profitability score, the more profitable the company is.
AMPH Solvency Score
Solvency Due Diligence
Amphastar Pharmaceuticals Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Score
Amphastar Pharmaceuticals Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AMPH Price Targets Summary
Amphastar Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for AMPH is 59.84 USD with a low forecast of 55.55 USD and a high forecast of 69.3 USD.
Dividends
Current shareholder yield for AMPH is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
AMPH Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. The company is headquartered in Rancho Cucamonga, California and currently employs 1,761 full-time employees. The company went IPO on 2014-06-25. The firm is primarily focused on developing, manufacturing, marketing and selling generic and injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (API) products. Its segments include Finished pharmaceutical products and API products. The Finished pharmaceutical products segment manufactures, markets and distributes Primatene Mist, glucagon, enoxaparin, naloxone, phytonadione, lidocaine, epinephrine, various critical and non-critical care drugs, as well as certain contract manufacturing. The API segment manufactures and distributes recombinant human insulin API and porcine insulin API for external customers and internal product development. Primatene Mist is an epinephrine inhalation product, which is indicated for the temporary relief of mild symptoms of intermittent asthma. Glucagon for injection emergency kit is indicated for the treatment of severe hypoglycemia.
Contact
IPO
Employees
Officers
The intrinsic value of one AMPH stock under the Base Case scenario is 62.15 USD.
Compared to the current market price of 45.46 USD, Amphastar Pharmaceuticals Inc is Undervalued by 27%.